This study follows, over the long term, people who were treated with an ex vivo gene therapy for sickle cell disease, assessing safety and effectiveness. It can enroll people who received the drug product for sickle cell disease in a bluebird bio-sponsored clinical study. It is a study without an assigned phase and enrolls by invitation.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Provision of written informed consent for this study by subject, or as applicable, subject's parent(s)/legal guardian(s) * Treated with drug product for therapy of sickle cell disease in a bluebird bio-sponsored clinical study Exclusion Criteria: * There are no exclusion criteria for this study